Literature DB >> 118997

Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children.

R Gold, M L Lepow, I Goldschneider, T F Draper, E C Gotshlich.   

Abstract

A cohort of infants, previously immunized once or twice between three and 12 months of age with vaccines containing polysaccharide of groups A and C Neisseria meningitidis, received boosters at two and five and one-half years of age with bivalent A/C vaccine. Antibody concentrations were measured by a radioactive antigen-binding assay. Concentrations of antibody to groups A and C N. meningitidis were 5.59 and 2.86 microgram/ml, respectively, by four years of age. After booster immunization at five and one-half years of age, concentrations of antibody to groups A and C N. meningitidis increased to 15.67 and 7.59 microgram/ml, respectively. Protective levels of antibody to group A meningococci may be achievable throughout early childhood by routine immunization with the A vaccine. Although the group C vaccine is effective in control of epidemics, the rapid decline in the concentration of antibody to group C meningococci following immunization of young children suggests that protection may not be long-lasting.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 118997     DOI: 10.1093/infdis/140.5.690

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  36 in total

Review 1.  Vaccine trials.

Authors:  C P Farrington; E Miller
Journal:  Mol Biotechnol       Date:  2001-01       Impact factor: 2.695

2.  HmbR, a hemoglobin-binding outer membrane protein of Neisseria meningitidis, undergoes phase variation.

Authors:  A R Richardson; I Stojiljkovic
Journal:  J Bacteriol       Date:  1999-04       Impact factor: 3.490

Review 3.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

4.  Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine.

Authors:  S E Maslanka; J W Tappero; B D Plikaytis; R S Brumberg; J K Dykes; L L Gheesling; K B Donaldson; A Schuchat; J Pullman; M Jones; J Bushmaker; G M Carlone
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

5.  Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children.

Authors:  Shousun C Szu; Keith P Klugman; Steven Hunt
Journal:  Vaccine       Date:  2014-03-13       Impact factor: 3.641

6.  Epidemiologic characteristics of an outbreak of serogroup C meningococcal disease and the public health response.

Authors:  P Houck; M Patnode; R Atwood; K Powell
Journal:  Public Health Rep       Date:  1995 May-Jun       Impact factor: 2.792

Review 7.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

8.  Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice.

Authors:  Zhigang Jin; Chiayung Chu; John B Robbins; Rachel Schneerson
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

9.  Assignment of Neisseria meningitidis serogroup A and C class-specific anticapsular antibody concentrations to the new standard reference serum CDC1992.

Authors:  P K Holder; S E Maslanka; L B Pais; J Dykes; B D Plikaytis; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  1995-03

10.  Molecular epidemiology of meningococcal disease in England and Wales 1975-1995, before the introduction of serogroup C conjugate vaccines.

Authors:  Joanne E Russell; Rachel Urwin; Stephen J Gray; Andrew J Fox; Ian M Feavers; Martin C J Maiden
Journal:  Microbiology (Reading)       Date:  2008-04       Impact factor: 2.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.